Multi-Specific Binding Molecules for Aberrant Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery challenges involve designing therapeutic molecules that are highly specific for aberrant cells related to malignancies and autoimmune diseases, while minimizing adverse reactions on healthy cells.
Innovation Solution
Development of proteinaceous molecules comprising at least two specific binding domains separated by linkers, forming a single polypeptide chain, to target multiple binding sites on aberrant cells with enhanced specificity and reduced risk of targeting normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-specific binding molecules are used to target aberrant cells, then the therapeutic effect is achieved, but the risk of adverse reactions on healthy cells increases due to off-target binding
Solution Approach 1:
The binding molecule is divided into multiple independent binding domains (e.g., VH1, VH2, VL1, VL2) that can independently recognize different epitopes. This segmentation allows the molecule to simultaneously target multiple unique binding sites on aberrant cells while reducing off-target binding to healthy cells, as the probability of all domains binding simultaneously to a healthy cell is extremely low.
Solution Approach 2:
The invention creates a composite binding molecule that integrates multiple different binding domains into a single polypeptide chain. This composite structure combines the specificity of different binding domains, enabling the molecule to recognize complex multi-epitope patterns unique to aberrant cells, thereby achieving high specificity while minimizing adverse reactions on healthy cells.
2Reliability
If multi-specific binding molecules are designed to target multiple binding sites, then the specificity for aberrant cells is improved, but the molecular complexity and manufacturing difficulty increase
Solution Approach 1:
Multiple binding domains that would traditionally be separate molecules are merged into a single polypeptide chain with defined connectivity. This merging reduces the number of separate components from four (VH1, VH2, VL1, VL2) to one integrated molecule, simplifying the system while maintaining the multi-specific binding capability. The linker regions provide flexible connection while preserving the functional independence of each binding domain.
Solution Approach 2:
The binding molecule is designed with universal modularity, where each binding domain can be independently selected and combined to target different epitopes. This multi-functional design allows the same molecular framework to be used for targeting various aberrant cells by simply changing the specific binding domains, reducing the need to develop entirely new complex molecules for different targets.
3Ease of manufacture
If traditional binding molecules are used, then the manufacturing process is simpler, but the ability to distinguish aberrant cells from normal cells is insufficient
Solution Approach 1:
The binding molecule is pre-designed with multiple binding domains configured to recognize specific combinations of epitopes that are characteristic of aberrant cells. This preliminary configuration of multi-specificity before administration allows the molecule to inherently discriminate between aberrant and normal cells through its binding pattern, eliminating the need for complex post-manufacturing characterization or combination of multiple separate drugs.
Solution Approach 2:
The invention changes the binding parameters from single-epitope recognition to multi-epitope recognition patterns. By configuring the molecule to require simultaneous binding to multiple specific epitopes with defined spatial relationships, the discrimination accuracy between aberrant and normal cells is dramatically improved while maintaining manufacturability through standard recombinant protein expression techniques.
Data Source
AI summary
Described are proteinaceous molecules comprising at least two, preferably three to six, binding domains that bind specifically to at least two different binding sites on aberrant cells. These multi-domain and multi-specific binding molecules are preferably used in selectively modulating biological processes. The provided binding molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.